82749-70-0 Usage
Uses
Used in Pharmaceutical Industry:
DCPIB is used as a research tool for studying the role of VSAC in pancreatic β-cells and its potential involvement in various physiological and pathological processes.
Used in Scientific Research:
DCPIB is used as a selective inhibitor of VSAC to investigate the channel's function and regulation in various cell types and tissues. It helps researchers understand the mechanisms underlying VSAC-mediated processes and identify potential therapeutic targets for diseases associated with VSAC dysfunction.
Biological Activity
Potent, selective blocker of the volume-sensitive anion channel (VSAC) in rat pancreatic β -cells (IC 50 ~ 2 μ M) and I Cl,swell in various cardiovascular tissues (IC 50 = 4.1 μ M in CPAE cells); blockade is voltage-independent. Displays minimal inhibition of other Cl - and K + currents (< 10% inhibition at 10 μ M). Inhibits glucose-stimulated insulin secretion in intact β -cells via VSAC inhibition and indirect K ATP channel activation. Reverses cell swelling-induced action potential duration shortening in atrial myocytes and inhibits astroglial swelling in vitro .
Check Digit Verification of cas no
The CAS Registry Mumber 82749-70-0 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 8,2,7,4 and 9 respectively; the second part has 2 digits, 7 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 82749-70:
(7*8)+(6*2)+(5*7)+(4*4)+(3*9)+(2*7)+(1*0)=160
160 % 10 = 0
So 82749-70-0 is a valid CAS Registry Number.
InChI:InChI=1/C22H28Cl2O4/c1-2-3-10-22(15-7-4-5-8-15)13-14-12-16(28-11-6-9-17(25)26)19(23)20(24)18(14)21(22)27/h12,15H,2-11,13H2,1H3,(H,25,26)
82749-70-0Relevant academic research and scientific papers
SWELL1-LRRC8 COMPLEX MODULATORS
-
, (2020/12/30)
The present invention is directed to various polycyclic compounds and methods of using these compounds to treat a variety of diseases including metabolic diseases such as obesity, diabetes, nonalcoholic fatty liver disease; cardiovascular diseases such as hypertension and stroke; neurological diseases, male infertility, muscular disorders, and immune disorders.
Treatment of brain injury due to gray matter edema with (indanyloxy) butanoic acids
-
, (2008/06/13)
The invention relates to the treatment and prevention of injury to the gray matter of the brain and to the spinal chord due to accidents, ischemic stroke, cardiac arrest, arrested breathing, Reye's syndrome and hydrocephalus by the administration of (indanyloxy)butanoic acids, their derivatives, analogs and salts thereof.
Agents for the treatment of brain injury. 1. (Aryloxy)alkanoic acids
Cragoe Jr.,Gould,Woltersdorf Jr.,Ziegler,Bourke,Nelson,Kimelberg,Waldman,Popp,Sedransk
, p. 567 - 579 (2007/10/02)
Blunt and ischemic injuries of the brain have been shown to result in swelling that is predominantly limited to a single cell type, the astrocyte, within the complex cellular mosaic of cerebral gray matter. Evaluation of various diuretic (aryloxy)acetic a
